Flow diagram of literature searches.

<p>^aAdditional records consisted of five yearly reports on <i>Toxocara</i> antibody detection in patients suspected of VLM or OLM; one book chapter on VLM <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001382#pntd.0001382-Beck1" target="_blank">[33]</a> and a master's thesis on toxocariasis in dogs <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001382#pntd.0001382-delaFeRodrguez1" target="_blank">[11]</a>. ^bReasons for exclusion were: 1. non-relevant association between the keywords (60%) (e.g., Cuba as name of the author, reports on <i>Toxocara</i> published in a Cuban journal, paper, or reference to paper conducted in Cuba in which toxocariasis is mentioned as differential diagnosis, papers on <i>Toxocara vitolorum</i>, etc.); 2. reference to a Cuban report on <i>Toxocara</i> seroprevalence data of Cuba (20%); and 3. replicates of the same report within the Google Scholar search (16%). One record was excluded because none of the co-authors was familiar with the language. ^cEligibility criteria were: 1. subject toxocara, toxocariasis, or larva migrans irrespective of the field or type of publication; and 2. new data about Cuba.</p

Chronological overview of reports on soil contamination with <i>Toxocara</i> spp. eggs in Cuba.

<p>Chronological overview of reports on soil contamination with <i>Toxocara</i> spp. eggs in Cuba.</p

Chronological overview of reports on <i>T. canis</i> infection in dogs in Cuba.

<p>Chronological overview of reports on <i>T. canis</i> infection in dogs in Cuba.</p

Yearly internal records of the IPK on the serodiagnosis of individuals suspected of human toxocariasis.

<p>Proportion of positive samples in a commercial TES-based ELISA (Diagnostic Automation, Inc., Calabasas, CA) performed by the Department of Parasitology of the IPK. Samples were from patients suspected of OLM or VLM and sent by clinicians across the country for serological confirmation of toxocariasis. No data are available for 2005 and 2008 due to inaccessibility of the commercial ELISA because of the trade embargo with the country. Serum samples were tested anonymously, and information on origin or on the differentiation between suspicion of OLM or VLM syndromes is not available, except for 2003 where all samples analyzed originated from the Ophthalmologic Institute “Ramón Pando Ferrer” and thus were suspicious of OLM. Follow-up of patients was not conducted by the IPK, preventing the confirmation of the suspected diagnosis. ^aData from 2009 are limited to samples received up to the beginning of August 2009.</p

Chronological overview of reports on taeniosis/cysticercosis in Cuba.

<p>This table summarizes the outcome of a literature search in the MEDLINE, PUBMED, LILACS (Latin American and Caribbean Health Science database, <a href="http://lilacs.bvsalud.org/en/" target="_blank">http://lilacs.bvsalud.org/en/</a>), and CUMED databases conducted with the keywords <i>Taenia solium</i>, cysticercosis, Cuba, and neurocysticercosis on October 15, 2012. In addition, references of retrieved reports were checked for additional information.</p>*<p>The title of the publication points to a case report of cerebral cysticercosis, but details on the case could not be obtained.</p>**<p>This study was recently conducted by our group (unpublished). PWE = people with epilepsy. NCC = neurocysticercosis.</p

Partially Sequenced Organisms, Decoy Searches and False Discovery Rates

Tandem mass spectrometry is commonly used to identify peptides, typically by comparing their product ion spectra with those predicted from a protein sequence database and scoring these matches. The most reported quality metric for a set of peptide identifications is the false discovery rate (FDR), the fraction of expected false identifications in the set. This metric has so far only been used for completely sequenced organisms or known protein mixtures. We have investigated whether FDR estimations are also applicable in the case of partially sequenced organisms, where many high-quality spectra fail to identify the correct peptides because the latter are not present in the searched sequence database. Using real data from human plasma and simulated partial sequence databases derived from two complete human sequence databases with different levels of redundancy, we could demonstrate that the mixture model approach in PeptideProphet is robust for partial databases, particularly if used in combination with decoy sequences. We therefore recommend using this method when estimating the FDR and reporting peptide identifications from incompletely sequenced organisms

Determinant factors for treatment choice in BUD patients’ health itineraries (numbered in order of importance).

<p>Determinant factors for treatment choice in BUD patients’ health itineraries (numbered in order of importance).</p

Health-seeking itineraries of patients in hospitals and endemic communities.

<p>Health-seeking itineraries of patients in hospitals and endemic communities.</p

Aetiology of BUD and first treatment options.

<p>Aetiology of BUD and first treatment options.</p

Delay prior to treatment seeking among hospital patients.

<p>Delay prior to treatment seeking among hospital patients.</p